Teprotumumab: a disease modifying treatment for graves’ orbitopathy
Abstract Background On 21st January 2020, the FDA approved Tepezza (teprotumumab-trbw) for the treatment of active Graves’ orbitopathy (GO) in adults. This approval was based on positive results from two multinational randomised double-blind placebo-controlled clinical trials. Discussion This articl...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-07-01
|
Series: | Thyroid Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13044-020-00086-7 |
id |
doaj-a3dd28462402418c913c1d0dee6d9ed2 |
---|---|
record_format |
Article |
spelling |
doaj-a3dd28462402418c913c1d0dee6d9ed22020-11-25T03:25:09ZengBMCThyroid Research1756-66142020-07-011311510.1186/s13044-020-00086-7Teprotumumab: a disease modifying treatment for graves’ orbitopathyMichelle Ting0Daniel G. Ezra1Adnexal Department, Moorfields Eye Hospital NHS Foundation TrustAdnexal Department, Moorfields Eye Hospital NHS Foundation TrustAbstract Background On 21st January 2020, the FDA approved Tepezza (teprotumumab-trbw) for the treatment of active Graves’ orbitopathy (GO) in adults. This approval was based on positive results from two multinational randomised double-blind placebo-controlled clinical trials. Discussion This article discusses the outcomes of those trials and the potential role of teprotumumab in altering current treatment paradigms in Graves’ orbitopathy. Future challenges are explored, including the need to confirm its disease-modifying effect, to establish its optimal position in the treatment pathway, and to define the appropriate subset of patients who would benefit from its use. Conclusions The results from these two large clinical trials have shown teprotumumab to have remarkable effects on multiple clinical outcomes in GO, particularly in its ability to reverse proptosis. It may herald a new era in the treatment of thyroid eye disease and could offer an alternative to surgery and its associated complications. Additional studies will continue to shape the treatment of GO and define the role of teprotumumab within the treatment paradigm.http://link.springer.com/article/10.1186/s13044-020-00086-7TeprotumumabGraves’ orbitopathyThyroid eye diseaseProptosisMonoclonal antibodiesInsulin-like growth Factor-1 receptor |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Michelle Ting Daniel G. Ezra |
spellingShingle |
Michelle Ting Daniel G. Ezra Teprotumumab: a disease modifying treatment for graves’ orbitopathy Thyroid Research Teprotumumab Graves’ orbitopathy Thyroid eye disease Proptosis Monoclonal antibodies Insulin-like growth Factor-1 receptor |
author_facet |
Michelle Ting Daniel G. Ezra |
author_sort |
Michelle Ting |
title |
Teprotumumab: a disease modifying treatment for graves’ orbitopathy |
title_short |
Teprotumumab: a disease modifying treatment for graves’ orbitopathy |
title_full |
Teprotumumab: a disease modifying treatment for graves’ orbitopathy |
title_fullStr |
Teprotumumab: a disease modifying treatment for graves’ orbitopathy |
title_full_unstemmed |
Teprotumumab: a disease modifying treatment for graves’ orbitopathy |
title_sort |
teprotumumab: a disease modifying treatment for graves’ orbitopathy |
publisher |
BMC |
series |
Thyroid Research |
issn |
1756-6614 |
publishDate |
2020-07-01 |
description |
Abstract Background On 21st January 2020, the FDA approved Tepezza (teprotumumab-trbw) for the treatment of active Graves’ orbitopathy (GO) in adults. This approval was based on positive results from two multinational randomised double-blind placebo-controlled clinical trials. Discussion This article discusses the outcomes of those trials and the potential role of teprotumumab in altering current treatment paradigms in Graves’ orbitopathy. Future challenges are explored, including the need to confirm its disease-modifying effect, to establish its optimal position in the treatment pathway, and to define the appropriate subset of patients who would benefit from its use. Conclusions The results from these two large clinical trials have shown teprotumumab to have remarkable effects on multiple clinical outcomes in GO, particularly in its ability to reverse proptosis. It may herald a new era in the treatment of thyroid eye disease and could offer an alternative to surgery and its associated complications. Additional studies will continue to shape the treatment of GO and define the role of teprotumumab within the treatment paradigm. |
topic |
Teprotumumab Graves’ orbitopathy Thyroid eye disease Proptosis Monoclonal antibodies Insulin-like growth Factor-1 receptor |
url |
http://link.springer.com/article/10.1186/s13044-020-00086-7 |
work_keys_str_mv |
AT michelleting teprotumumabadiseasemodifyingtreatmentforgravesorbitopathy AT danielgezra teprotumumabadiseasemodifyingtreatmentforgravesorbitopathy |
_version_ |
1724598666313859072 |